Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy
- Phyllis August, MD, MPH
Phyllis August, MD, MPH
- Ralph A Baer, MD Professor of Research in Medicine
- Director, Hypertension Center
- Division of Nephrology & Hypertension
- Weill Cornell Medical College
- Section Editors
- Louise Wilkins-Haug, MD, PhD
Louise Wilkins-Haug, MD, PhD
- Section Editor — Prenatal Diagnosis and Genetics
- Professor of Obstetrics, Gynecology, and Reproductive Biology
- Harvard Medical School
- George L Bakris, MD
George L Bakris, MD
- Editor-in-Chief — Nephrology
- Section Editor — Hypertension
- Professor of Medicine
- The University of Chicago
Several antihypertensive agents, including methyldopa, calcium channel blockers, hydralazine, and labetalol, have a good safety profile for use in pregnant women. In contrast, animal and human data suggest that drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) are associated with an increased risk of fetopathy. This topic will review the known adverse effects of RAAS inhibitors in pregnancy. The treatment of hypertension in pregnant and breastfeeding women is discussed separately. (See "Management of hypertension in pregnant and postpartum women".)
DRUGS TO AVOID
Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are associated with an increased risk of fetopathy (discussed below), and should be avoided in pregnancy [1-11].
Valsartan/sacubitril is the newest drug of this type and is a combination of an angiotensin receptor blocker and a neprilysin inhibitor (ARNI). Although no data are available in pregnancy, this drug has a similar mechanism of action and should not be administered to pregnant women .
RISK OF ADVERSE FETAL/NEONATAL EFFECTS
There are significant fetal risks associated with the use of RAAS inhibitors at all stages of pregnancy.
A systematic review of pregnancy outcome following exposure to ACE inhibitors or ARBs included 72 reports and 186 cases . Approximately one-third of the cases involved first trimester exposure. Major findings were:
- Shotan A, Widerhorn J, Hurst A, Elkayam U. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 1994; 96:451.
- Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354:2443.
- Broughton Pipkin F, Symonds EM, Turner SR. The effect of captopril (SQ14,225) upon mother and fetus in the chronically cannulated ewe and in the pregnant rabbit. J Physiol 1982; 323:415.
- Keith IM, Will JA, Weir EK. Captopril: association with fetal death and pulmonary vascular changes in the rabbit. Proc Soc Exp Biol Med 1982; 170:378.
- Ferris TF, Weir EK. Effect of captopril on uterine blood flow and prostaglandin E synthesis in the pregnant rabbit. J Clin Invest 1983; 71:809.
- Schubiger G, Flury G, Nussberger J. Enalapril for pregnancy-induced hypertension: acute renal failure in a neonate. Ann Intern Med 1988; 108:215.
- Hanssens M, Keirse MJ, Vankelecom F, Van Assche FA. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol 1991; 78:128.
- Pryde PG, Sedman AB, Nugent CE, Barr M Jr. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol 1993; 3:1575.
- Tabacova S, Little R, Tsong Y, et al. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf 2003; 12:633.
- Hünseler C, Paneitz A, Friedrich D, et al. Angiotensin II receptor blocker induced fetopathy: 7 cases. Klin Padiatr 2011; 223:10.
- Nadeem S, Hashmat S, Defreitas MJ, et al. Renin Angiotensin System Blocker Fetopathy: A Midwest Pediatric Nephrology Consortium Report. J Pediatr 2015; 167:881.
- Hubers SA, Brown NJ. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation 2016; 133:1115.
- Bullo M, Tschumi S, Bucher BS, et al. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 2012; 60:444.
- Caton AR, Bell EM, Druschel CM, et al. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension 2009; 54:63.
- Lennestål R, Otterblad Olausson P, Källén B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 2009; 65:615.
- Li DK, Yang C, Andrade S, et al. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 2011; 343:d5931.
- Bateman BT, Patorno E, Desai RJ, et al. Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations. Obstet Gynecol 2017; 129:174.
- Gubler MC. Renal tubular dysgenesis. Pediatr Nephrol 2014; 29:51.
- Gubler MC, Antignac C. Renin-angiotensin system in kidney development: renal tubular dysgenesis. Kidney Int 2010; 77:400.
- Millan MA, Carvallo P, Izumi S, et al. Novel sites of expression of functional angiotensin II receptors in the late gestation fetus. Science 1989; 244:1340.
- Guron G, Friberg P. An intact renin-angiotensin system is a prerequisite for normal renal development. J Hypertens 2000; 18:123.
- Hård AL, Wennerholm UB, Niklasson A, Hellström A. Severe ROP in twins after blockage of the renin-angiotensin system during gestation. Acta Paediatr 2008; 97:1142.
- Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355:637.
- Bos-Thompson MA, Hillaire-Buys D, Muller F, et al. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth. Ann Pharmacother 2005; 39:157.
- Guron G, Mölne J, Swerkersson S, et al. A 14-year-old girl with renal abnormalities after brief intrauterine exposure to enalapril during late gestation. Nephrol Dial Transplant 2006; 21:522.
- Laube GF, Kemper MJ, Schubiger G, Neuhaus TJ. Angiotensin-converting enzyme inhibitor fetopathy: long-term outcome. Arch Dis Child Fetal Neonatal Ed 2007; 92:F402.
- Simonetti GD, Baumann T, Pachlopnik JM, et al. Non-lethal fetal toxicity of the angiotensin receptor blocker candesartan. Pediatr Nephrol 2006; 21:1329.
- Velázquez-Armenta EY, Han JY, Choi JS, et al. Angiotensin II receptor blockers in pregnancy: a case report and systematic review of the literature. Hypertens Pregnancy 2007; 26:51.
- Karthikeyan VJ, Ferner RE, Baghdadi S, et al. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnancies. J Hypertens 2011; 29:396.
- DRUGS TO AVOID
- RISK OF ADVERSE FETAL/NEONATAL EFFECTS
- First-trimester exposure
- Second and third trimester exposure
- Exposure through breast milk
- HYPOTHESES FOR PATHOGENESIS OF ADVERSE EFFECTS
- LONG-TERM PROGNOSIS OF SYMPTOMATIC NEONATES
- USE OF ACE INHIBITORS AND ARBS IN WOMEN OF CHILDBEARING POTENTIAL
- Our approach
- INFORMATION FOR PATIENTS
- SUMMARY AND RECOMMENDATIONS